Philogen
innovating targeting

Press Release

The MedChem division of the Italian Chemical Society (SCI) awarded two Prizes to Philochem employees: Samuele Cazzamalli (Head of Chemistry) and Sara Puglioli (Research Scientist)

Siena (Italy), May, 29th 2025 – Philogen S.p.A., a clinical-stage biotechnology company focused on antibody and small molecule-based targeted therapeutics, is pleased to announce that two members of Philochem's Chemistry Team have been selected to receive two prizes from the Medicinal Chemistry Division of the Italian Chemical Society (SCI).

In recognition of his industrial application of tumor-targeting small molecules, Samuele Cazzamalli will be awarded the 2025 Medicinal Chemistry Division Prize by the Italian Chemical Society. This annual award aims to recognize significant research activities in the field of Medicinal Chemistry that have been the subject of publication in journals or patent applications.

In recognition of her outstanding PhD Thesis work, Sara Puglioli will be awarded the prize for the best PhD Thesis in Medicinal Chemistry by the Medicinal Chemistry Division of the Italian Chemical Society. This annual award aims to recognize the quality of work carried out by recent PhD graduates during their thesis period in all areas of Medicinal Chemistry.

Dr. Cazzamalli is currently the Head of Chemistry, and Dr. Puglioli is a Research Scientist working in the DNA-Encoded Library (DEL) field. They both work at Philochem, the Swiss subsidiary of the Philogen group that acts as a discovery center focusing on chemical pharmaceutical products and technologies.

The ceremony will take place at the XXIX National Meeting on Medicinal Chemistry in Parma (14-17 September), during which Dr. Cazzamalli and Dr. Puglioli will give an oral presentation about their work.

About Philochem and the Philogen Group

Philochem is a fully owned subsidiary of the Philogen Group, a Swiss-Italian, clinical-stage biotechnology company listed on the Italian Stock Exchange. Philogen is engaged in the discovery and development of novel pharmaceutical and biopharmaceutical products. Philogen's strategy is to selectively deliver bioactive agents (such as radionuclides, cytokines or drugs) to the site of disease using antibodies or small organic ligands. This technology has generated a strong proprietary pipeline of clinical-stage products and preclinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem near Zurich, Switzerland. Philogen has

signed agreements with several major pharmaceutical companies. For more information, please visit www.philogen.com and www.philochem.ch.

* * *

FOR MORE INFORMATION: Philogen - Investor Relations IR@philogen.com - Emanuele Puca | Investor Relations